Revive Therapeutics Ltd (OTCMKTS: RVVTF) recently offered its shareholders an update on the clinical trials of its investigation on the uses of Bucillamine. The company is...
Revive Therapeutics Limited (OTCMKTS: RVVTF) recently announced that it received approval from the U.S. Food and Drug Administration to utilize Orphan Drug Designation to reduce the...
Revive Therapeutics Ltd. (OTCMKTS: RVVTF) has offered an update regarding its psilocybin drug development initiatives that include IRB approval to commence second phase trial for methamphetamine...
Revive Therapeutics Ltd. (OTCMKTS: RVVTF) has announced that the company will expand research with Bucilamine as a potential Omicron variant treatment. Bucillamine is an oral treatment...
Revive Therapeutics Ltd (OTCMKTS: RVVTF) has submitted an application to the US FDA for an Orphan Drug Designation for Bucillamine in ischemia-reperfusion injury (IRI)prevention during a...
Revive Therapeutics Inc. (OTCMKTS: RVVTF) has signed a research partnership agreement with clinical psychedelics biotechnology firm PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate psilocybin delivery using...
Revive Therapeutics Ltd (OTCMKTS: RVVTF) has provided an update on the US FDA Phase 3 clinical study evaluating Bucillamine’s efficacy and safety in patients having Mild...
Revive Therapeutics Ltd (OTCMKTS: RVVTF) is a life sciences corporation that focuses on researching and developing therapeutics that can be used to treat rare medical disorders. The...
Revive Therapeutics Ltd (OTCMKTS:RVVTF) acquired IP to Psilocybin of PharmaTher Inc., which is a subsidiary of Newscope Capital Corporation (OTCMKTS:PHRRF), for CAD 10 million. Revive Therapeutics...
It seems like Revive Therapeutics Ltd (OTCMKTS:RVVTF) has promising progress in its operations. The company’s plans for initiating a Phase 3 study on Bucillamine are rolling...
